Interviews

Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.

Those with class III obesity showed 7%+ weight loss with high engagement; Stephanie Kim, MD, MPH, talks GLP-1 complementarity and prospective study needs.

Fear of CPAP deters patients with OSA from seeking care. Experts call for early diagnosis with oral devices and warn payers about the cost of delays.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

Creatinine, not just a diabetes diagnosis, should trigger SGLT2 inhibitor use in CKD, says Sandra Chaparro, MD.

Alexander Spira, MD, PhD, FACP, FASCO, on why sarcoma diagnosis is often delayed and how community-academic collaboration speeds treatment.

The myeloma space has undergone tremendous transformation recently, says Prerna Mewawalla, MD, including CAR T-cell therapies and bispecific antibodies.

Elena Koundourakis, PhD, discusses phase 3 trial improvements in cognition, REM normalization, and nighttime sleep quality in patients with narcolepsy.

Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, says.

Joseph K. Han, MD, discusses verekitug, unmet needs in CRSwNP, and why better biologic therapies remain necessary.

EHA 2026 highlights include advances in immunotherapy across blood cancers.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.

Adam Spira, PhD, MA, discusses how composite measures of sleep health may offer a modifiable target to reduce dementia risk.

Alexander Spira, MD, PhD, discusses why sarcoma treatment lags other cancers, citing tumor heterogeneity and inconsistent immunotherapy response as barriers.

Richard Bogan, MD, discusses trial data coming out of the VIBRANCE studies for patients with narcolepsy type 2 and idiopathic hypersomnia.

Peter Hotez, MD, discusses which patients may benefit most from newly approved oral COVID-19 postexposure prophylaxis.

Nathanael Hwang discusses how EHR-based machine learning models are adding value to patients with obstructive sleep apnea.

Salma Patel, MD, shares findings from the implementation of combination therapy recommendations for patients with chronic insomnia.

Nipocalimab showed rapid responses within 1 week in warm autoimmune hemolytic anemia (wAIHA), as well as a favorable safety profile.

Referral hurdles, months-long sleep testing waits, and CPAP reluctance delay OSA care; at-home screening and oral appliances expand access.

Baseline QOL is an independent prognostic factor for survival in AML, with global QOL carrying the largest HR, according to Fabio Efficace, PhD, MSc.

Sunil Sharma, MD, discusses the consequences of not diagnosing patients with sleep-disordered breathing during hospital admission.

In a VESALIUS-CV subgroup analysis, evolocumab cut MACE by 29% in high-risk diabetes, reinforcing intensive LDL lowering for CV risk reduction.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Specialty pharmacies reduce administrative burden and total cost of care as advanced therapies move to community sites, Fran Gregory, PharmD explains.

Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.